Company Overview of TransMolecular, Inc.
As of March 2011, TransMolecular, Inc. was acquired by Morphotek, Inc. TransMolecular, Inc. engages in discovering, developing, and commercializing therapies for glioma, metastatic brain tumors, and cancers. It offers TM601, a synthetic a polypeptide based on amino acid peptide derived from scorpion venom, which is used to treat cancer. The company was founded in 1996 and is based in Cambridge, Massachusetts.
840 Memorial Drive
Cambridge, MA 02139
Founded in 1996
Key Executives for TransMolecular, Inc.
TransMolecular, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|Genetic Vectors, Inc.||United States|
|Hitachi Chemical Research Center, Inc.||United States|
|Magceutics, Inc.||United States|
|Alice Therapeutics, Inc.||United States|
|Collabra Pharma, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Cayey | Becton DickinsonPosted: Dec 23
- Hyattsville, MD | University of Maryland University CollegePosted: Mar 04
- South San Francisco, CA | GenentechPosted: Mar 08
- San Mateo, CA |Posted: Mar 06
Sponsored Financial Commentaries
To contact TransMolecular, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.